Celldex Therapeutics (CLDX) Q4 2021 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: Celldex ended 2021 with $408 million in cash, providing a runway through the end of 2025.

Funding: A follow-on offering was completed in 2021, strengthening the balance sheet.

2Strategic Updates and Business Highlights

CDX-0159 Development:

Positive Phase 1 results for CDX-0159, a mast cell-depleting antibody, were reported, showing a 95% complete response rate in chronic inducible urticaria (CIndU) patients after a single dose.

Initiated two additional studies for CDX-0159: a Phase 1 healthy volunteer study for a subcutaneous formulation and a Phase 1b study for prurigo nodularis.

Positive interim data from a chronic toxicology study in nonhuman primates supports upcoming Phase 2 trials.

Plans to expand indications for CDX-0159 to include eosinophilic esophagitis (EoE), with a Phase 2 study expected to start in Q4 2022.

3Forward Guidance and Outlook

Upcoming Milestones:

Phase 2 trials for chronic spontaneous urticaria (CSU) and CIndU are set to begin in Q2 2022.

Data from the Phase 1 multiple ascending dose IV study in CSU will be presented at EAACI 2022 in July.

Long-term Vision: The company aims to leverage its expertise in antibody drug discovery to develop treatments for diseases with significant unmet needs, particularly focusing on CDX-0159.

4Bad News, Challenges, or Points of Concern

Toxicology Findings:

Observed impacts on spermatogenesis in nonhuman primates during chronic toxicology studies, although these effects are expected to be reversible. The company is conducting further reproductive toxicology studies.

Enrollment Challenges: Difficulty in enrolling patients for the cholinergic urticaria cohort due to challenges in identifying appropriate candidates.

Competitive Landscape: The market for urticaria treatments is becoming increasingly competitive, with other products targeting similar pathways, although the company believes its mechanism of action is distinct.

5Notable Q&A Insights

Patient Enrollment: The Phase 1b study for CSU will include patients refractory to biologic therapy, and the company does not require data from the 4.5 mg cohort to proceed with Phase 2.

EoE Mechanism: There is a known relationship between mast cells and eosinophils, with mast cells potentially influencing eosinophil infiltration, which is critical for EoE treatment.

Subcutaneous Formulation: The subcutaneous formulation of CDX-0159 is expected to be well-tolerated, with plans for eventual self-administration by patients. Overall, Celldex Therapeutics reported a strong financial position and promising clinical data for CDX-0159, while also facing challenges related to toxicology findings and patient enrollment in specific cohorts. The company remains focused on advancing its pipeline and expanding indications for its lead product.